Build Your Own Case Study | Obesity: Treating the Whole Patient
This activity is supported by an educational grant from Lilly.
Click Here to Manage Email Alerts
CE Activity Release Date: April 27, 2023
CE Activity Expiration Date: April 26, 2024
Time to Complete activity: 60 minutes
DESCRIPTION
Obesity is a chronic, progressive, relapsing disease that impacts health and quality of life. In individuals with obesity, there are many contributors to its development and persistence, including lifestyle, social, and economic factors. If left untreated, obesity can be a primary driver of serious health consequences. By treating obesity first, complications arising from obesity may improve or resolve. Given the severity of the disease, there is a need for clinicians in primary and specialty care settings to diagnose and treat obesity so that patients can receive the most appropriate treatment and care. Evidence-based treatment options, including anti-obesity medications, are emerging for adults and children. In this immersive virtual Build Your Own Case Study | Obesity: Treating the Whole Patient, navigate through your toughest clinical challenges while leading experts reinforce essential topics, such as:
- Medical consequences and comorbidities of obesity
- Application of adiposity measures, including BMI and waist circumference
- Latest clinical evidence of new and emerging anti-obesity medications
- Best practices in shared decision-making and starting the conversation with your patients
TARGET AUDIENCE
This activity is intended for primary care clinicians (eg, physicians, NPs, PAs, nurses, pharmacists) who provide care for individuals with obesity.
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Identify common medical consequences and comorbidities of the chronic primary disease of obesity.
- Assess factors that lead to a diagnosis of obesity, including BMI and waist circumference, for patients who may have overweight/obesity.
- Evaluate the safety and efficacy of the most recently approved and emerging AOMs.
- Utilize shared decision making when discussing effective weight loss options, including new and emerging pharmacotherapies.
AGENDA
- Part 1: Prioritizing obesity as a chronic disease
- Part 2: Build Your Own Case Study
- Case Study 1 – Annual Well Visit Patient
- Case Study 2 – Sick Visit Appointment
- Case Study 3 – Comorbidity Follow up | Labs Visit
- Part 3: The Library
ACCREDITATION, SUPPORT AND CREDIT
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.5 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-019-H01-P
Type of Activity: Knowledge
AAPA Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until April 19, 2024. PAs should only claim credit commensurate with the extent of their participation.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
SUPPORT STATEMENT
This activity is supported by an educational grant from Lilly.
DISCLOSURE & CONFLICT OF INTEREST POLICY
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
FACULTY DISCLOSURES
Planner/Presenter
Jamy D. Ard, MD
Professor, Department of Epidemiology & Prevention
Wake Forest School of Medicine
Co-Director, Weight Management Center
Atrium Health Wake Forest Baptist
Winston-Salem, NC
Advisory Board/Consultant: Boehringer Ingelheim, Intuitive, Lilly, Nestle, Novo Nordisk, United Health Group, Weight Watchers
Research Grant: Epitomee, KVK Tech, Lilly, Nestle, Weight Watchers
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Calibrate
Planner/Presenter
Scott Kahan, MD, MPH
Director, National Center for Weight and Wellness
Washington, DC
Advisory Board/Consultant: Currax, Gelesis, Lilly, Vivus
Planner/Presenter
Holly F. Lofton, MD, DABOM
Clinical Associate Professor of Surgery and Medicine
Director, Medical Weight Management Program
NYU Langone Weight Management Program
New York, NY
Advisory Board/Consultant: Novo Nordisk
Research Grant: Lilly, Novo Nordisk
Speakers’ Bureau: Novo Nordisk
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Currax
Planner/Presenter
Jay H. Shubrook, DO, FACOFP, FAAFP
Professor, Primary Care Department
Diabetologist
Touro University California
College of Osteopathic Medicine
Vallejo, CA
Advisory Board/Consultant: Abbott, Bayer, Nevro, Novo Nordisk
Independent Contractor: Abbott
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: AstraZeneca
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
All of the relevant financial relationships of individuals for this activity have been mitigated.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org.
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
ABOUT THIS ACTIVITY
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
